Has Joseph Kam Chiu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $11,507 in general payments to Joseph Kam Chiu, MD across 287 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joseph Kam Chiu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joseph Kam Chiu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joseph Kam Chiu, MD

Radiation Oncology · Lincoln, NENPI 1265426175

Payments from drug & device makers

$11,507in general payments, 2019–2025

Across 287 payments — averaging $40.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$6K
Johnson & Johnson$369
Novartis$358
Merck$326
Octapharma USA, Inc.$262
Pfizer$250
plus $3K from 54 others

What the payments were for

Consulting fees$6,30055%
Food & beverage$5,17845%
Education$290%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	12	$6,482
Johnson & Johnson(2 entities)	22	$369
Novartis	22	$358
Merck	18	$326
Octapharma USA, Inc.	2	$262
Pfizer	14	$250
AbbVie	9	$190
Takeda Pharmaceuticals U.S.A., Inc.	10	$186
Seagen Inc.	10	$159
Eisai Inc.	9	$156
Incyte Corporation	9	$135
Amgen	7	$132
Bayer	8	$131
Daiichi Sankyo Inc.	6	$107
Genentech USA, Inc.	6	$98
Sanofi	6	$96
Tersera Therapeutics LLC	5	$95
Astellas Pharma US Inc	5	$88
Regeneron Healthcare Solutions, Inc.	4	$82
Lilly USA, LLC	6	$78
Gilead	5	$77
Taiho Oncology, Inc.	4	$72
Puma Biotechnology, Inc.	5	$68
Karyopharm Therapeutics Inc.	4	$64
Stemline Therapeutics Inc.	3	$64
Pharmacyclics LLC, An Abbvie Company	4	$62
Servier Pharmaceuticals LLC	3	$62
Amneal Pharmaceuticals LLC	2	$61
Ipsen Biopharmaceuticals, Inc	3	$52
Mirati Therapeutics, Inc.	2	$49
Adaptive Biotechnologies Corporation	3	$48
Sobi, Inc	3	$48
E.r. Squibb & Sons, L.L.C.	3	$47
Genmab U.S., Inc.	2	$47
Jazz Pharmaceuticals Inc.	3	$46
Novocure Inc.	3	$45
Foundation Medicine, Inc.	2	$45
Beone Medicines USA, Inc.	2	$43
Boehringer Ingelheim	2	$43
CSL Behring	2	$42
Blueprint Medicines Corporation	2	$40
Iovance Biotherapeutics, Inc.	2	$40
Kyowa Kirin, Inc.	2	$39
Blue Earth Diagnostics	2	$37
Boston Scientific	2	$35
Myovant Sciences Inc.	2	$34
Visionrt, Inc.	1	$34
EMD Serono, Inc.	2	$34
AVEO Pharmaceuticals, Inc.	2	$34
G1 Therapeutics, Inc.	2	$29
CTI Biopharma Corp.	2	$28
Agios Pharmaceuticals, Inc.	2	$26
Beigene USA, Inc.	1	$24
Clovis Oncology, Inc.	2	$22
Array Biopharma Inc	1	$22
Pharmaessentia USA Corporation	1	$19
Bristol Myers Squibb	1	$19
Sumitomo Pharma America, Inc.	1	$18
Tolmar Pharmaceuticals, Inc.	1	$18
Syndax Pharmaceuticals, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

IMFINZI$6,300
OCTAGAM IMMUNE GLOBULIN (HUMAN)$240

How this compares

$11,507 in reported general payments places this provider in the 90th percentile of 32 radiation oncology providers in Nebraska.

See all radiation oncology providers in Nebraska →

Medicare billing

Part B allowed, 2024

$1,262,889

Medicare patients

510

Services billed

7,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lidocaine Hcl ViscousLidocaine Hcl	12	$174

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Lincoln

Jacqueline KellyLincoln$5K
Mark StavasLincoln$4K
Phillip HynesLincoln$2K
Kevin YieeLincoln$1K
Raju RaoLincoln$109
Bennett BarriosLincoln$23
Hadi ZahraNorfolk$15K
Alireza MirmiranOmaha$13K
Michael BaineOmaha$4K
Tien Shew HuangOmaha$2K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →